Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHAT | P28329 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28666492 | 0.94 | NPC1 (0.50) | MAPTNPC1CYP1A2KDM4EMEN1 | |
| SCHEMBL3283370 | 0.91 | KDM4E (0.33) | MAPTNPC1CYP1A2KDM4EMEN1 | |
| SCHEMBL2173175 | 0.82 | TSHR (0.30) | — | |
| SCHEMBL2173547 | 0.77 | APP (0.50) | MAPTNPC1CYP1A2KDM4EMEN1 | |
| SCHEMBL2204079 | 0.73 | HDAC8 (0.31) | — | |
| SCHEMBL6564250 | 0.72 | ALDH1A1 (0.46) | MAPTNPC1CYP1A2KDM4EMEN1 | |
| SCHEMBL148575 | 0.69 | TSHR (0.35) | CYP1A2ALDH1A1CA12CA2CA9 | |
| SCHEMBL21936342 | 0.69 | TSHR (0.35) | CYP1A2ALDH1A1CA12CA2CA9 | |
| SCHEMBL6562841 | 0.69 | NPC1 (0.42) | MAPTNPC1CYP1A2KDM4EMEN1 | |
| SCHEMBL15469239 | 0.68 | APP (0.57) | MAPTNPC1CYP1A2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700860-B1 | POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS, INTERMEDIATE THEREFOR, PROCESS FOR PRODUCING POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS, AND PROCESS FOR PRODUCING INTERMEDIATE FOR POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS | JAPAN SCIENCE & TECH AGENCY (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7973190-B2 | Polycyclic fused ring type π-conjugated organic material, intermediate therefor, process for producing polycyclic fused ring type π-conjugated organic material, and process for producing intermediate of polycyclic fused ring type π-conjugated organic material | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090143605-A1 | POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL, INTERMEDIATE THEREFOR, PROCESS FOR PRODUCING POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL, AND PROCESS FOR PRODUCING INTERMEDIATE OF POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1700860-A1 | POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS, INTERMEDIATE THEREFOR, PROCESS FOR PRODUCING POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS, AND PROCESS FOR PRODUCING INTERMEDIATE FOR POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIALS | Japan Science and Technology Agency (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143605-A1 | POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL, INTERMEDIATE THEREFOR, PROCESS FOR PRODUCING POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL, AND PROCESS FOR PRODUCING INTERMEDIATE OF POLYCYCLIC FUSED RING TYPE PI-CONJUGATED ORGANIC MATERIAL | THEM6, RICTOR, FARSB | MAPT 3419/4885NPC1 646/4885CYP1A2 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.